1. Home
  2. BTDR vs WVE Comparison

BTDR vs WVE Comparison

Compare BTDR & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTDR

Bitdeer Technologies Group

N/A

Current Price

$8.04

Market Cap

2.2B

Sector

Technology

ML Signal

N/A

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

N/A

Current Price

$15.28

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTDR
WVE
Founded
2021
2012
Country
Singapore
Singapore
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.4B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
BTDR
WVE
Price
$8.04
$15.28
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
16
Target Price
$25.10
$30.44
AVG Volume (30 Days)
7.5M
2.8M
Earning Date
01-01-0001
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
$89.44
N/A
Revenue Next Year
$68.00
$15.93
P/E Ratio
N/A
N/A
Revenue Growth
N/A
149.43
52 Week Low
$6.84
$5.28
52 Week High
$27.80
$21.73

Technical Indicators

Market Signals
Indicator
BTDR
WVE
Relative Strength Index (RSI) 32.30 66.97
Support Level $7.55 $15.23
Resistance Level $14.47 $18.50
Average True Range (ATR) 0.88 0.69
MACD -0.30 0.26
Stochastic Oscillator 9.98 98.64

Price Performance

Historical Comparison
BTDR
WVE

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: